FDA approval sought for UGN 102 in low-grade, intermediate-risk, non–muscle-invasive, bladder cancer – Urogen Pharma
A new drug application (NDA) has been submitted to the FDA seeking the approval of mitomycin for intravesical solution (UGN 102) for the treatment of patients with low-grade,… read more.
